WO2011037349A3 - Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof - Google Patents

Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof Download PDF

Info

Publication number
WO2011037349A3
WO2011037349A3 PCT/KR2010/006270 KR2010006270W WO2011037349A3 WO 2011037349 A3 WO2011037349 A3 WO 2011037349A3 KR 2010006270 W KR2010006270 W KR 2010006270W WO 2011037349 A3 WO2011037349 A3 WO 2011037349A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
delivery system
drug delivery
specific
controlling
Prior art date
Application number
PCT/KR2010/006270
Other languages
French (fr)
Other versions
WO2011037349A8 (en
WO2011037349A2 (en
Inventor
Sei-Kwang Hahn
Seung Kyu Yoon
Wonhee Hur
Ki Su Kim
Jiseok Kim
Original Assignee
Postech Academy-Industry Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Postech Academy-Industry Foundation filed Critical Postech Academy-Industry Foundation
Publication of WO2011037349A2 publication Critical patent/WO2011037349A2/en
Publication of WO2011037349A8 publication Critical patent/WO2011037349A8/en
Publication of WO2011037349A3 publication Critical patent/WO2011037349A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a method of controlling the target specificity of drug delivery system including the hyaluronic acid (HA) derivative, a target specific drug delivery system and a target non-specific long-acting drug delivery system. The regulation of the substitution ratio of carboxyl group in HA derivative controls the target specific or target non-specific long-acting property of the drug delivery system including the HA derivative.
PCT/KR2010/006270 2009-09-23 2010-09-14 Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof WO2011037349A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090090113A KR20110032561A (en) 2009-09-23 2009-09-23 Method of controling target specific drug delivery, target specific drug delivery system, and target non-specific long-acting drug delivery system
KR10-2009-0090113 2009-09-23

Publications (3)

Publication Number Publication Date
WO2011037349A2 WO2011037349A2 (en) 2011-03-31
WO2011037349A8 WO2011037349A8 (en) 2011-05-05
WO2011037349A3 true WO2011037349A3 (en) 2011-10-06

Family

ID=43796344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006270 WO2011037349A2 (en) 2009-09-23 2010-09-14 Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof

Country Status (2)

Country Link
KR (1) KR20110032561A (en)
WO (1) WO2011037349A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104910569B (en) * 2015-06-03 2017-03-01 西安交通大学 A kind of can biological reducing hyaluronic acid/poly- (NεAcryloyl group L lysine) double-network hydrogel and preparation method thereof
JP2019522042A (en) * 2016-05-12 2019-08-08 インシツ バイオロジクス、インク． Hydrogel bio-delivery vehicle
KR101905863B1 (en) * 2016-10-11 2018-10-08 아주대학교산학협력단 Pharmaceutical Composition for Preventing or Treating of Inflammatory Diseases and Metabolic Diseases Comprising hyaluronic acid Nanoparticles
IT201600117042A1 (en) * 2016-11-18 2018-05-18 Fidia Farm Spa HYALURONIC ACIDS SULFATE FUNCTIONALIZED WITH DOPAMINE
CN107488240B (en) * 2017-09-11 2019-08-27 中国工程物理研究院核物理与化学研究所 Tyrasamine/Diphosphonate-hyaluronic acid high-molecular compound and hydrogel and preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
WO2007014784A2 (en) * 2005-08-03 2007-02-08 Fidia Farmaceutici S.P.A. Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
WO2007014784A2 (en) * 2005-08-03 2007-02-08 Fidia Farmaceutici S.P.A. Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUN JU OH ET AL.: "Target specific and long-acting delivery of protein, pepti de, and nucleotide therapeutics using hyaluronic acid derivatives", J.CONT.RE 1., vol. 141, 13 September 2009 (2009-09-13), pages 2 - 12 *

Also Published As

Publication number Publication date
WO2011037349A8 (en) 2011-05-05
WO2011037349A2 (en) 2011-03-31
KR20110032561A (en) 2011-03-30

Similar Documents

Publication Publication Date Title
AU2016219654A1 (en) Crystallization method and bioavailability
WO2010096394A3 (en) Aldehyde-tagged protein-based drug carriers and methods of use
WO2012125987A3 (en) Delivery system
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012018881A3 (en) Methods and compositions for the regulation of rna
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
UA104613C2 (en) Alkylamine-substituted dicyanopyridines and amino acid ester prodrugs thereof
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2012140650A3 (en) Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
WO2010088565A8 (en) Nucleic acid delivery using modified chitosans
WO2007106738A3 (en) Acrylated hyaluronic acid
WO2011153323A8 (en) Compositions and methods directed to treating liver fibrosis
MX352245B (en) Pharmaceutical formulation comprising a biopharmaceutical drug.
WO2009129387A3 (en) Cationic lipids and uses thereof
WO2011037349A8 (en) Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof
WO2010120389A8 (en) Polymeric drug delivery systems and processes for producing such systems
WO2011089595A3 (en) Sustained-release nucleic acid matrix compositions
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2010023310A3 (en) The an3 protein complex and its use for plant growth promotion
WO2009074970A3 (en) Means for delivery of nucleic acids active for gene silencing using synthetic polymers
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof
EP2131849A4 (en) Compositions and methods for delivery of anti-cancer agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10818990

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10818990

Country of ref document: EP

Kind code of ref document: A2